Search clinical trials for: Pandemic Influenza Vaccine

Total 6578 results

McMaster University
Canadian Institutes of Health Research (CIHR)

Completed

Live Versus Inactivated Influenza Vaccine Study in Hutterite Children

Influenza

Canada
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions

Influenza, Human

Germany
The University of Hong Kong

Completed

Intradermal Influenza Vaccine in the Young

Influenza Viral Infections

China
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Avian Influenza | Immunisation

United States
Novavax

Not yet recruiting

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

COVID-19
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Healthy Volunteers | Influenza Immunization

United States
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine

Influenza

United States
University of Alabama at Birmingham

Active, not recruiting

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

Influenza

United States
Hadassah Medical Organization

Unknown

Influenza Vaccination at a Reduced Dose Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem

HIV Infections | Influenza | Acquired Immune Deficiency Syndrome

Israel
Sahlgrenska University Hospital, Sweden

Completed

Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients

Organ Transplantation

Sweden
Northwestern University

Completed

Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients

Influenza

United States
Universitas Padjadjaran
Universiti Sains Malaysia; Biofarma

Completed

Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)

Diabetes Mellitus | Chronic Kidney Diseases | Vaccine Reaction | Influenza

Indonesia
University of Pennsylvania

Active, not recruiting

Flu Vaccine Responses in the Setting of Melanoma Treatment

Viral Vaccines

United States
Novartis Vaccines

Completed

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

Seasonal Influenza

Italy
Jiangsu Province Centers for Disease Control and...

Completed

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

Influenza

China
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza, Human

United Kingdom
University of Michigan
American College of Allergy, Asthma and Immunology

Completed

Safe Administration of Flu Vaccine to Egg Allergic Children (SAFE)

Egg Allergy

United States
Research Institute for Biological Safety Problems
Research Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...

Completed

Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)

Influenza, Human

Kazakhstan
Novartis Vaccines

Completed

Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.

Influenza Disease

Italy
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009

Interpandemic Influenza

Italy
Crucell Holland BV

Completed

Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains

Influenza

Switzerland
Novartis
Novartis Vaccines

Completed

Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

Influenza

Poland
University of British Columbia
GlaxoSmithKline; Canadian Institutes of Health Research (CIHR)

Completed

Safety and Protectiveness of the Seasonal Influenza Vaccine for 2010-2011 (PCIRNRT06)

Influenza

Canada
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults

Influenza | Swine-origin A/H1N1 Influenza

France
Abramson Cancer Center at Penn Medicine

Recruiting

BRCA1/2 Flu Vaccine

BRCA1 Mutation | BRCA2 Mutation

United States
Butantan Institute

Completed

Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2018) (FLU-06-IB)

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Orthomyxoviridae Infections | Physiological Effects of Drugs | Vaccines

Brazil
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

Influenza | Seasonal Influenza

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza, Vaccine

Germany
Novartis Vaccines

Completed

Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases

Influenza Disease

Italy
The University of Hong Kong
Food and Health Bureau, Hong Kong

Completed

Brief Influenza Vaccine Education to Pregnant Women

Pregnancy | Infectious Disease | Influenza

Hong Kong
Tel-Aviv Sourasky Medical Center

Unknown

Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine

Rheumatoid Arthritis | Cellular Immune Response

Israel
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia

Leukemia | Infection

United States
National Institute of Allergy and Infectious Diseases...
Baylor College of Medicine; University of Pittsburgh; Ann & Robert H Lurie Children... and other collaborators

Not yet recruiting

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients (PSOT)

Influenza | Transplantation Infection | Immunization; Infection

United States
Vanderbilt University Medical Center
University of Alabama at Birmingham; Duke University; University of Washington; Northwestern University Feinberg School of Medicine

Recruiting

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Influenza | Transplantation Infection | Immunization; Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Hoffmann-La Roche

Completed

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Canada, United States
Bayer
CureVac

Withdrawn

COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older (CV-NCOV-011)

Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
Vanderbilt-Ingram Cancer Center

Completed

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

Adult Stem Cell Hematopoetic Transplant

United States
Duke University
Centers for Disease Control and Prevention; Kaiser Permanente

Completed

Fever After Simultaneous Versus Sequential Vaccination in Young Children

Fever | Febrile Seizure | Fever After Vaccination

United States
Jiangsu Province Centers for Disease Control and...

Completed

Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

COVID-19

China
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine

Vaccine Reaction | Influenza | Influenza, Human | Vaccination; Infection | Influenza Viral Infections

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Safety and Immunogenicity of Fluzone® in Healthy Children

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

France
Celgene

Completed

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Germany
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States

3

Subscribe